Evidence map›Paper›PMID 24026239›Full record

ArticleGlycobiology2013

Identifying human milk glycans that inhibit norovirus binding using surface plasmon resonance.

Jing Shang, Vladimir E Piskarev, Ming Xia, Pengwei Huang, Xi Jiang, Leonid M Likhosherstov, Olga S Novikova, David S Newburg, Daniel M Ratner

Open access · bronzeAbstract read
In one paragraph

Article in Glycobiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 74 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Viruses and Human Milk: Transmission or Protection?Advances in nutrition (Bethesda, Md.) · 2023
    Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Inhibitory Effects ofViruses · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. A Survey of Analytical Techniques for Noroviruses.Foods (Basel, Switzerland) · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Jing ShangDepartment of Bioengineering, University of Washington, 3720 15th Avenue NE, Seattle, WA 98195, USA.
Vladimir E Piskarev
Ming Xia
Pengwei Huang
Xi Jiang
Leonid M Likhosherstov
Olga S Novikova
David S Newburg
Daniel M Ratner
Cincinnati Children's Hospital Medical Center · USN.D. Zelinsky Institute of Organic Chemistry · RUUniversity of Washington · USA. N. Nesmeyanov Institute of Organoelement Compounds · RUBoston College · US

Funding

Surface Analysis Facility for Biomedical ProblemsP41EB002027 · NIBIB · UNIVERSITY OF WASHINGTON · PI CASTNER, DAVID G · 2003 to 2019
$17.6M
VIRAL GASTROENTERITIS PATHOGENSP01HD013021 · NICHD · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MORROW, ARDYTHE L · 1985 to 2013
$15.0M
Novel vaccine against NorovirusR01AI089634 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI JIANG, XI · 2010 to 2014
$4.7M
Novel broad spectrum therapeutic glycans against Category B pathogensU01AI075563 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI NEWBURG, DAVID S. · 2007 to 2011
$4.5M
Oligosaccharide moieties of human milk glycans that inhibit pathogensR01HD061930 · NICHD · MASSACHUSETTS GENERAL HOSPITAL · PI NEWBURG, DAVID S. · 2009 to 2014
$3.0M
NIAID NIH HHS AI075563NIAID NIH HHS R01 AI089634NIBIB NIH HHS P41 EB002027NICHD NIH HHS HD013021NICHD NIH HHS HD061930NICHD NIH HHS R01 HD061930
6 · The paper itself

Abstract

Human milk glycans inhibit binding between norovirus and its host glycan receptor; such competitive inhibition by human milk glycans is associated with a reduced risk of infection. The relationship between the presence of specific structural motifs in the human milk glycan and its ability to inhibit binding by specific norovirus strains requires facile, accurate and miniaturized-binding assays. Toward this end, a high-throughput biosensor platform was developed based on surface plasmon resonance imaging (SPRi) of glycan microarrays. The SPRi was validated, and its utility was tested, by measuring binding specificities between defined human milk glycan epitopes and the capsids of two common norovirus strains, VA387 and Norwalk. Human milk oligosaccharide (HMOS)-based neoglycoconjugates, including chemically derived neoglycoproteins and oligosaccharide-glycine derivatives, were used to represent polyvalent glycoconjugates and monovalent oligosaccharides, respectively, in human milk. SPRi binding results established that the glycan motifs that bind norovirus capsids depend upon strain; VA387 capsid interacts with two neoglycoproteins, whereas Norwalk capsid binds to a different set of HMOS motifs in the form of both polyvalent neoglycoproteins and monovalent oligosaccharides. SPRi competitive binding assays further demonstrated that specific norovirus-binding glycans are able to inhibit norovirus capsid binding to their host receptors. A polyvalent neoglycoconjugate with clustered carbohydrate moieties is required for the inhibition of VA387 capsid binding to host receptor glycans, whereas both monovalent oligosaccharides and polyvalent neoglycoconjugates are able to inhibit Norwalk capsid binding to its host receptor. Binding of HMOS and HMOS-based neoglycoconjugates to norovirus capsids depends upon the specific strain characteristics, implying that HMOS and their polyvalent derivatives are potential anti-adhesive agents for norovirus prophylaxis.

Indexed as

Surface Plasmon ResonanceAnimalsBinding SitesCapsidHumansMicrobial Sensitivity TestsMilkNorovirusPolysaccharidesStructure-Activity RelationshipPolysaccharidesanti-adhesiveshost–pathogen interactionshuman milk glycansnorovirussurface plasmon resonance

Identifiers

PMID24026239
PMCPMC3816630
OpenAlexW2153599991

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.